Mutations of the methyl CpG binding protein 2 (MeCP2) gene are a major cause of Rett syndrome. To investigate whether the expression of this gene was related to JC virus (JCV) infection, we examined brains of four progressive multifocal leukoencephalopathy (PML) patients. JCV infection was confirmed by immunohistochemical labeling with antibodies against JCV VP1, Agnoprotein and large T antigen. MeCP2 expression was examined by immunohistochemistry using a specific polyclonal antibody against MeCP2. In normal brains and uninfected cortices of PML brains, MeCP2 expression was observed in the nuclei of neurons, but not observed in glial and endothelial cell nuclei. In PML brains, however, intense immunolabeling was observed in abnormally enlarged glial nuclei of JCV-infected cells. The JCV infection was verified by immunolabeling against JCV VP1, Agnoprotein and large T antigen. Double immunolabeling using antibodies against large T antigen (visualized as blue) and MeCP2 (visualised as red) revealed purple JCV infected nuclei, which confirmed that the JCV infected nuclei expressed MeCP2. When we examined four MeCP2 related proteins, named as methyl CpG binding domains (MBD) 1, 2, 3, and 4, only MBD1 exhibited similar results to MeCP2. We conclude that MeCP2 is highly expressed in the JCV infected nuclei of PML brain and these results may provide a new insight into the mechanism which regulates the MeCP2 expression in glial cells by the infection of JCV.
Abstract
Mutations of the methyl CpG binding protein 2 (MeCP2) gene are a major cause of Rett syndrome. To investigate whether the expression of this gene was related to JC virus (JCV) infection, we examined brains of four progressive multifocal leukoencephalopathy (PML) patients. JCV infection was confirmed by immunohistochemical labeling with antibodies against JCV VP1, Agnoprotein and large T antigen. MeCP2 expression was examined by immunohistochemistry using a specific polyclonal antibody against MeCP2. In normal brains and uninfected cortices of PML brains, MeCP2 expression was observed in the nuclei of neurons, but not observed in glial and endothelial cell nuclei. In PML brains, however, intense immunolabeling was observed in abnormally enlarged glial nuclei of JCV-infected cells. The JCV infection was verified by immunolabeling against JCV VP1, Agnoprotein and large T antigen. Double immunolabeling using antibodies against large T antigen (visualized as blue) and MeCP2 (visualised as red) revealed purple JCV infected nuclei, which confirmed that the JCV infected nuclei expressed MeCP2. When we examined four MeCP2 related proteins, named as methyl CpG binding domains (MBD) 1, 2, 3, and 4, only MBD1 exhibited similar results to MeCP2. We conclude that MeCP2 is highly expressed in the JCV infected nuclei of PML brain and these results may provide a new insight into the mechanism which regulates the MeCP2 expression in glial cells by the infection of JCV. 
MATERIALS AND METHODS Autopsy cases
Four brains, obtained at autopsy from PML patients, and two 'control' brains originating from patients with non-neurological disease were used for the present studies. The basic disease resulting in PML and the age and gender of the patients were as follows: hypogammaglobulinemia (27-year-old female), 17 two cases of AIDS (38-year-old male with hemophilia A, and 50-year-old male), and chronic renal failure with a longstanding hemodialysis (74-year-old female). 18 
Antibodies
Our original antibodies specific to JC virus capsid protein VP1 and Agnoprotein were used as previously reported. Immunohistochemical staining Formalin-fixed paraffin-embedded sections of PML brains were deparaffinized with xylene and dehydrated with ethanol, treated with normal goat serum and 1% H 2 O 2 methanol to stop endogenous peroxidase activity, and thereafter incubated with the primary antibody as described above. As the present studies were the first trial of immunohistochemistry, we have diluted antibodies 1,000 times, so that no-back ground staining was detected, and no cytoplasmic staining was observed. Selective neuronal staining was obtained in the cerebellar cortex and colonic Auerbach's plexus by taking into account that in rats MeCP2 mRNA expression is detected in these tissues and cells. 19 After incubation with the biotinylated second antibodies, immunoreactive products were either visualized by 3,3'-diaminobenzidine tetrahydrochloride (DAB) as brown, or by amino-ethyl carbazole (AEC) as red. For double immunolabeling, the sections were first incubated with an anti-large T monoclonal antibody which was visualized as blue by nitro-blue tetrazolium chloride/ 5-bromo-4-chloro-3'-indolylphosphatase (NBT/BCIP) via alkaline phosphatase reaction.
Then, the sections were incubated with rabbit antibodies against MeCP2, and were visualized as red by AEC. Hence, cells containing both proteins are revealed as dark red in the tissue sections. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
RESULTS
Immunohistochemically, MeCP2 was expressed in the nuclei of neuronal cells of the cerebral cortices of normal brains and in non-affected regions of PML brains (Fig. 1A) .
Both astrocytic and oligodendroglial nuclei remained unstained. In addition, endothelial cell nuclei were also unstained (Fig. 1A) .
In the PML brain, there were enlarged basophilic nuclei in the demyelinated lesions, characteristic of JCV infection. These nuclei were immunohistochemically labeled with antibodies against JCV VP1, Agnoprotein and large T antigen (Fig. 1B) . These findings confirm that enlarged basophilic nuclei in the demyelinated foci were actually infected with JCV.
MeCP2 immunolabeling of the PML brains disclosed that enlarged basophilic nuclei were also labeled with MeCP2 ( Fig. 1C) , while glial cell nuclei in the non-affected regions were unstained. The distribution of positive nuclei was quite similar to those of JCV VP1 large-T antigen. Moreover, the intensity of immunolabeling was stronger than the nuclei nuclear staining of the normal brains and also resembled that of JCV VP1 and Agnoprotein (unpublished observation).
To confirm whether the JCV infected nuclei were simultaneously labeled with MeCP2, double immunolabeling was performed. The paraffin sections were first immunolabeled with JCV large-T, which is visualized as blue, then incubated with antibodies against MeCP2 which is visualized as red. Most of enlarged nuclei were dark red, resulting from both JCV large-T and MeCP2 immunolabeling, while only a few small nuclei stained red or blue. Hence, both JCV proteins and MeCP2 were localized in the same nuclei in PML brains.
With reference to the MeCP2 related proteins, there was intense MBD-1 immunolabeling in enlarged nuclei of the PML brains, similar to MeCP2, but MBD-4 was only weakly immunolabeled in the enlarged nuclei and MBD-2 and MBD-3 were not expressed. In addition, MBD-2 was positive in the neurons of the cerebral cortices. 15 However, recent studies using animal models have demonstrated that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and may function as both an activator and a repressor of the target genes. 16 MeCP2 mRNA has been examined by in situ hybridization in rats and is shown to be expressed in the ganglion cells and intestinal epithelium of the small intestine, Purkinje cells and other neurons in the brain, and in cells of the testis, 19 In humans, expression is also found in the colonic mucosa and colon cancers. 20 Neuronal expression found in rats is similar to the immunohistochemical findings revealed in the present study. Although many neuronal degenerative several neurodegenerative and mental retarded disorders have been known to be associated with functional deficiency of MeCP2, 21 data suggesting an interaction of MeCP2 with viral proteins has been limited. Krithivas et al. examined the mechanism of latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV), and found that MeCP2 is one of the LANA binding proteins, and reported that MeCP2 is important for plays a role in the binding of LANA to bind to with chromosomes. 22 Griffiths and Whitehouse examined the monkey herpesvirus saimiri (HVS) homologous to KSHV, and found that the gene essential for HSV HVS episomal maintenance associates with MeCP2. 23 These reports suggest that MeCP2 is an important protein for viral episomal persistence and for subsequent persistent infection. As JCV is also asymptomatically persistent in human tissues, possibly in an episomal state in the latently infected cells, MeCP2 may be an essential factor explaining for its persistency. However, expression of MeCP2 in the cells with lytic infection has not been examined. Our present study demonstrates that high expression is observed in lytically infected cells with JCV, and hence we should also examine MeCP2 expression in the persistently infected cells. Alternatively, to better understand the present results, it is important to study MeCP2 expression in lytically infected cells with KSHV or HVS.
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